InvestWiser

Arctic Bioscience AS

ABSOslo BørsHealthcareMarket value 73 m NOK
2.69NOK 0.0%
last day · Price as of 18 November 2026

The answer first

Does Arctic Bioscience beat the market?

No, Arctic Bioscience has not beaten the market over the last year.

Arctic Bioscience−21.1%Oslo Børs (OSEBX)+29.5%
  • The ranking · Quality, value and trend combined

    Better than 23% of Nordic stocks

    • Quality41
    • Value49
    • Trend23

    No. 121 of 195 in healthcare

Max for seven days

Follow Arctic Bioscience with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Arctic Bioscience

From today, at a price of 2.69 NOK. Write why you follow Arctic Bioscience, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Arctic Bioscience

Your first answer is free, no account needed.

Do you own Arctic Bioscience, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Arctic Bioscience and a few more. Free, no card.

Past year against the exchange and Super Stock
Arctic Bioscience−27.7%Oslo Børs (OSEBX)+29.5%Super Stock+44.6%
17 November 202518 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Arctic Bioscience has fallen 21.1% over the past year, including dividends.
  • Overall, Arctic Bioscience ranks better than 23% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 91.7%. The price is 91.0% below its peak now.

Who owns Arctic Bioscience? See the major shareholders and their stakes

What do analysts think of Arctic Bioscience?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

23

Quality, value and trend together. Better than 23% of Nordic stocks.

No. 121 of 195 in healthcare

Quality41
The company · Fundamentals: the accounts

Medium An average company: the accounts are neither especially strong nor weak.

No. 145 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.45
  • Asset turnoverSales divided by everything the company owns0.16
  • Return on equityProfit divided by equity−27.9%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value49
The price · Valuation: the multiples

Medium Fair price: about the same as a typical Nordic stock.

No. 53 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equity0.5
  • P/SPrice divided by sales1.6
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend23
The share price · Technical: the price trend

Low Headwind in the share price: it has done worse than most over the last year.

No. 116 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months−6.3%
  • 6 months−19.9%
  • 9 months−19.7%
  • 12 months−21.1%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
+12.1%
3 years, per year
−34.3%
5 years, per year
−30.8%
Year to date
−18.0%
Largest fall, 3 years
−91.7%
From a peak to the bottom
From the peak now
−91.0%
How far the price is from the peak
Volatility, 1 year
76.8%
How much the price swings over a year
Beta, 1 year
−0.40
How much the price moves when the market moves

Return with dividends reinvested.

About Arctic Bioscience

Arctic Bioscience AS is a company in healthcare, listed on Oslo Børs. The share trades in NOK. It has around 19 employees.

Arctic Bioscience AS, a clinical-stage biotechnology company, engages in developing and commercializing pharmaceutical and nutraceutical ingredients based on bioactive marine compounds in Norway, the United States, Europe, and Asia Pacific. The company is developing HRO350, a novel oral drug which is in phase IIb for the treatment of mild-to-moderate psoriasis; and the HeROPA study, an international phase IIb clinical trial. It also sells nutraceuticals as an intermediary and finished goods products under the ROMEGA brand name. Arctic Bioscience AS was incorporated in 2011 and is headquartered in Ørsta, Norway.

See the full analysis of Arctic Bioscience.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Oslo Børs

Explore the stock market